14 min readAuthor: MojeInBodyUpdated

Mounjaro, Wegovy and muscle: what to track during GLP-1 weight loss

Weight loss with GLP-1 or dual GIP/GLP-1 medicines such as semaglutide or tirzepatide usually comes mainly from fat, but absolute lean mass can also fall. Lean mass includes muscle, water, organs and other non-fat tissue, so it must not be relabelled automatically as “muscle loss.” InBody cannot assess the medicine’s safety; it can supplement repeated tracking of estimated muscle and fat alongside strength, function, nutrition and medical care.

Mounjaro, Wegovy and muscle: what to track during GLP-1 weight loss

What GLP-1 medications are and why they matter beyond diabetes

GLP-1 medications are named after glucagon-like peptide-1, a hormone the body releases after eating that affects appetite, stomach emptying and blood sugar. The group includes active substances such as semaglutide and liraglutide, while the newer tirzepatide combines a GLP-1 and GIP effect. These medications were first used for type 2 diabetes and are now increasingly prescribed specifically for weight management.

Semaglutide is the active substance in products such as Wegovy and Ozempic; Mounjaro contains tirzepatide. Sharing an active substance does not mean having the same approved indication or dosing; the doctor assesses the appropriate medicine. For body-composition tracking, substantial weight loss changes several body compartments at once. Scale weight alone therefore does not describe the full treatment outcome.

Why weight loss is not the same as fat loss

Trials of semaglutide and tirzepatide report reductions in both fat and lean mass. Meta-analyses also show that relative lean mass can be preserved or improve because fat generally falls more. A single claim such as “one quarter of weight loss is muscle” is therefore not a universal rule for every medicine or person.

Lean mass is not synonymous with skeletal muscle, and short-term changes also reflect water and glycogen. Functional context requires strength, everyday performance, food intake and activity alongside body-composition estimates.

Sarcopenia is not diagnosed from lean-mass kilograms alone. European consensus gives priority to low muscle strength and confirms the diagnosis with low muscle quantity or quality. Older, frail or rapidly losing patients need risk-based assessment by their clinical team.

Less lean mass but greater strength: how is that possible?

Muscle quantity, quality and what you can do with it are different things. In the prospective SEMALEAN study, published online in October 2025 and in the January 2026 journal issue, 106 people with obesity receiving semaglutide completed a year of follow-up. DXA lean soft tissue fell initially and then stabilised; handgrip strength improved at the one-year visit. A decline in one measure therefore did not mean a simultaneous decline in strength in this group. There was no randomised control group, so the study does not establish that everyone will gain strength or that the medicine alone caused the improvement.

The SURPASS-3 MRI analysis in people with type 2 diabetes offered another perspective: tirzepatide was associated with reduced muscle fat infiltration as well as reduced muscle volume. The authors describe the infiltration change as potentially favourable. This was a post-hoc analysis of a particular trial, not evidence that all users are protected against muscle loss. InBody does not directly image this infiltration.

In practice, combine body-composition trends with repeated handgrip testing and everyday function. Difficulty walking, standing up or carrying groceries matters even when estimated SMM on the result sheet looks stable. Pain, fatigue and testing technique also affect strength, so grip strength alone cannot identify the cause of a change.

What InBody actually shows during GLP-1-supported weight loss

A bathroom scale gives only total weight. InBody uses bioimpedance to estimate fat mass and skeletal muscle mass separately, so repeated trends can be followed. It does not directly image muscle, and early changes may partly reflect water or glycogen.

A more favorable trend is usually one in which fat accounts for most of the loss while strength and estimated muscle are preserved as well as possible. A repeated fall in estimated muscle, strength or function should prompt a review with the clinical team, not an independent medication change.

DXA, MRI and InBody: why study percentages cannot be converted into your muscle loss

When a study reports lean mass, check the tissue compartment and measurement method. For example, DXA in the SURMOUNT-1 substudy distinguished fat from lean soft tissue excluding bone minerals. That compartment contains more than skeletal muscle. The broader term fat-free mass (FFM) includes the bone component too; InBody estimated skeletal muscle mass (SMM) is a different measure.

A report that part of the lost weight was lean mass therefore cannot be rewritten as the percentage of muscle you personally lost. For your own trend, compare the same measure on the same device under similar conditions. A result from a different type of device may be useful, but it is not automatically the next point on the same curve.

What each method adds to weight-loss monitoring
MethodWhat it assessesWhat it cannot establish
DXAEstimates fat, lean soft tissue and bone minerals.A fall in lean mass does not directly measure pure muscle loss or strength.
MRI in researchVolume of selected muscles and, depending on the protocol, fat infiltration.One region is not interchangeable with whole-body SMM or a functional test.
InBody / BIAEstimates composition, including fat, SMM and water, from impedance.Does not image muscle tissue or fat infiltration; fluid status affects the estimate.
Handgrip strengthForce during a standardised squeeze of a dynamometer.Does not give kilograms of muscle or identify why strength changed.

Why two 5 kg losses can look completely different

The same five kilograms of scale weight can accompany different fat and muscle-estimate trends. The model below helps frame follow-up questions; it does not establish how much of the loss was actual muscle.

This is a simplified illustration, not a specific measured result, but it shows why body composition, not just scale weight, is worth tracking during GLP-1 therapy.
MetricFat-dominant weight lossWeight loss with falling estimated muscle
Fat massDrops clearly and makes up most of the loss.Drops, but is not the only part of the loss.
Estimated muscle massApproximately stable across repeated measurements.Repeatedly falls; review fluid status, strength and function too.
Resting energy expenditureEstimated BMR may fall less if fat-free mass is preserved.Estimated BMR may fall more if estimated fat-free mass falls.
What to add beyond InBodyStrength, activity, protein intake and everyday function.Strength, activity, intake, symptoms and clinical review.

How to lower the risk of losing muscle during GLP-1 therapy

A joint professional advisory emphasizes adequate high-quality food and protein, prevention of very low energy or micronutrient intake, and risk-based monitoring. A safe target cannot be derived from body weight alone; age, kidney function, treatment tolerance and the clinical plan matter.

On 1 December 2025 the World Health Organization issued its first global guideline on GLP-1 therapy for obesity in adults. It conditionally recommends liraglutide, semaglutide and tirzepatide for long-term treatment of adults with obesity (BMI 30 or higher), excluding pregnant women. A second, also conditional recommendation, based on low-certainty evidence, states that people on this treatment may be offered a structured intensive programme focused on diet and physical activity. Even for WHO, the medicine is therefore not a stand-alone solution.

More protein alone is unlikely to preserve muscle without resistance or strength exercise. Training must be adapted to baseline function, joints, symptoms and access; a generic weekly target is a goal to individualize, not a condition for medication safety.

Persistent vomiting, inability to eat or drink adequately, rapid functional decline or signs of dehydration need clinical review. Supplements such as creatine do not replace nutrition, training or medical monitoring.

What if you have little appetite during treatment?

Reduced appetite can make weight loss easier, but it does not show that your diet meets your needs. If you become full quickly, record meals, drinks and any nausea for a few days. A dietitian can use the record to distinguish low intake from tolerance problems and develop a plan you can actually manage.

Discuss smaller portions, meal distribution and protein sources you tolerate with your clinician or dietitian. Protein powder may supplement intake, but it does not replace adequate total energy, varied food or management of side effects. Kidney disease or another clinical context requires individual assessment before adopting a sports-protein target.

Contact the treating team if you repeatedly vomit, cannot eat or drink adequately, or develop weakness and dizziness. Further food restriction or changing the dose based on InBody is not the solution. A lower scale number is not a reason to overlook a deterioration in health.

What to record before treatment and bring to follow-up

A useful baseline combines composition, function and food intake. If treatment has already started, begin now; label the first available scan as the baseline for subsequent comparisons, not as your pre-treatment state. Do not delay prescribed treatment to obtain a scan.

Bring dated results and notes to follow-up rather than just your body-fat percentage. Together, you can review whether fat is falling, how estimated muscle is changing, whether function is maintained and whether you can eat adequately. The list supports a conversation; it is not a treatment-success score.

For follow-up, prepare one page with the same fields for each date. A note such as “several days of nausea, less food and more difficulty with usual walking after a prescribed dose change” tells the clinician something different from “I lost 3 kg”. It describes events occurring together, rather than proving causation.

A one-page treatment follow-up record
AreaWhat to include
TimelineStart date and prescribed treatment changes; dates of weighing and testing
Food and fluidsWhat you can eat and drink, nausea, vomiting or other difficulties and their duration
Strength and daily functionThe same safe everyday task or standardized grip test; what has become harder
MeasurementsFull report, device, conditions and weight; mark method changes separately
Question for the teamFor example: my intake has not recovered and I feel weaker; how should my clinician and dietitian adapt the plan?
  • Date, body weight, fat mass in kg and estimated SMM; keep the complete result sheet.
  • Device and conditions: approximate time, last meal, exercise and unusual changes in hydration.
  • Handgrip strength with a comparable protocol, if available; note changes in walking, standing up and daily tasks.
  • A brief record of intake, activity and food-tolerance problems; record treatment changes for your doctor rather than adjusting treatment based on a scan.

How often to measure so the comparison actually means something

For results to be comparable, measurements should happen under similar conditions — a similar time of day, similar hydration, no training right before the test. That matters for any InBody tracking, but it matters more during rapid weight loss, because more is changing in the body at once.

There is no universal InBody testing interval during GLP-1 treatment. Repeating a measurement after several weeks may help show a longer-term trend, but short-term changes in estimated muscle can also reflect fluid shifts. Set the timing around the pace of weight loss and the clinical plan; do not wait for another scan if new symptoms or weakness appear.

The result history in the client portal is useful here, since it lines up measurements over time and shows how the fat and muscle curves move together, rather than comparing only the last two results in isolation. A longer timeline makes it much easier to tell a real trend apart from normal variation between visits.

2026 research: can lean mass be better preserved during weight loss?

New medicine combinations are also being studied for lean-mass preservation. EMBRAZE, published on 8 June 2026 in Nature Medicine, randomised 102 adults with overweight or obesity to tirzepatide plus apitegromab or placebo. After 24 weeks, the combination group lost less DXA lean mass despite similar total weight loss.

This was a small phase 2 trial; exploratory assessments showed no notable physical-function benefit, and longer-term outcomes need further research. It is not a guide to routine obesity treatment or a reason to seek an additional medicine independently. The useful message is that research distinguishes scale weight, composition and function; none of these represents all the others.

When it is time to talk to a doctor

InBody does not evaluate the safety or suitability of GLP-1 treatment, does not assess dosing, and does not replace lab work or follow-up with the prescribing doctor. It is a supporting tool for tracking body composition alongside medical care, not instead of it.

If estimated muscle repeatedly falls, discuss measurement conditions, intake and training at follow-up. Contact the treating team sooner for significant fatigue, dizziness, loss of strength in everyday tasks or other unusual symptoms. These do not necessarily mean muscle loss, but the result sheet cannot identify their cause. Dose adjustment or stopping treatment belongs with the doctor.

FAQ

Frequently asked questions

Do you lose muscle while losing weight on Mounjaro, Wegovy or Ozempic?

Trials show a fall in lean mass alongside the larger fall in fat. Lean mass is not identical to muscle and also includes water and other tissue. Repeated composition estimates should be interpreted with strength, function, nutrition and medical context.

How can I tell if I'm losing fat or muscle?

A regular scale cannot tell you, since it only shows total weight change. InBody estimates fat and skeletal muscle mass; follow both trends under similar testing conditions and consider strength and everyday function too. A single scan cannot confirm actual muscle loss.

Do exercise and protein actually help preserve muscle during GLP-1 treatment?

Resistance exercise and adequate protein are leading supportive strategies, but the size of their effect during GLP-1 treatment and the right plan vary. Targets should be adapted to health status and the prescribing team’s guidance.

Can InBody replace medical checkups during GLP-1 treatment?

No. InBody is a supporting tool for tracking body composition, not a replacement for medical monitoring, lab tests or dose adjustments. Decisions about the treatment itself always belong to the prescribing doctor.

How often should I measure InBody while losing weight on GLP-1 medication?

There is no universal interval. During faster weight loss, a repeat scan after several weeks may help show a longer-term trend, but the timing should fit the clinical plan. Fluid shifts can affect short-term estimates; seek clinical advice for new symptoms or weakness without waiting for the next scan.

Can lean mass fall while strength improves?

Yes; SEMALEAN reported this pattern, for example. Tissue quantity and strength are different measures, but one study does not guarantee an individual outcome. Track composition, strength and everyday function together.

Is protein powder enough when my appetite is low?

Protein powder can supplement protein, but it does not address total energy intake, dietary variety or treatment side effects. If eating or drinking adequately is difficult, discuss tolerance and a nutrition plan with the treating team.

Want to track how body composition and strength change during weight loss?

During GLP-1-supported weight loss, repeated estimates of fat and muscle matter more than one scale number. InBody can show the direction of those estimates; grip strength and everyday function add information that bioimpedance cannot measure.